SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors

(2021) Hidekatsu Yanai et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Early combination therapy of empagliflozin and linagliptin exerts beneficial effects on pancreatic β cells in diabetic db/db mice

(2021) Yoshiro Fushimi et al.   Scientific Reports

SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action

(2020) Milton Packer   DIABETES CARE

Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure

(2020) Décio L. Eizirik et al.   Nature Reviews Endocrinology

Dysfunction of Persisting β Cells Is a Key Feature of Early Type 2 Diabetes Pathogenesis

(2020) Christian M. Cohrs et al.   Cell Reports

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control

(2020) Martin R. Cowie et al.   Nature Reviews Cardiology

Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice

(2020) Rui Wei et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Differential effects of sodium-glucose cotransporter 2 inhibitor and low-carbohydrate diet on body composition and metabolic profile in obese diabetic db/db mice

(2020) Toru Kusakabe et al.   BMJ Open Diabetes Research & Care

SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans

(2020) Heeyoung Chae et al.   Molecular Metabolism

No direct effect of SGLT2 activity on glucagon secretion

(2019) Rune E. Kuhre et al.   DIABETOLOGIA

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients

(2019) Aino Latva-Rasku et al.   DIABETES CARE

Glucolipotoxicity, β-Cells, and Diabetes: The Emperor Has No Clothes

(2019) Gordon C. Weir   DIABETES

Endoplasmic reticulum stress, degeneration of pancreatic islet β-cells, and therapeutic modulation of the unfolded protein response in diabetes

(2019) Rajarshi Ghosh et al.   Molecular Metabolism

Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice

(2018) Toshiyuki Takasu et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better

(2018) Tomohiko Kimura et al.   DIABETES OBESITY & METABOLISM

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus

(2018) Hussein Al Jobori et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men

(2018) Patrik Rorsman et al.   PHYSIOLOGICAL REVIEWS

Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages

(2018) Kiyohiko Takahashi et al.   Scientific Reports

SGLT2 knockout prevents hyperglycemia and is associated with reduced pancreatic β-cell death in genetically obese mice

(2018) Michael J. Jurczak et al.   Islets

Early administration of dapagliflozin preserves pancreatic β-cell mass through a legacy effect in a mouse model of type 2 diabetes

(2018) Ayumi Kanno et al.   Journal of Diabetes Investigation

Mechanisms of β-cell dedifferentiation in diabetes: recent findings and future research directions

(2017) Mohammed Bensellam et al.   JOURNAL OF ENDOCRINOLOGY

Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis

(2017) Chunguang Chen et al.   Molecular Metabolism

Metabolic Stress and Compromised Identity of Pancreatic Beta Cells

(2017) Avital Swisa et al.   Frontiers in Genetics

Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice

(2016) Seizo Okauchi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Pancreatic β-cell identity in diabetes

(2016) M. S. Remedi et al.   DIABETES OBESITY & METABOLISM

The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin

(2016) Matthias Kern et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β -cell function and reduction of insulin resistance

(2016) Hideaki Kaneto et al.   Journal of Diabetes

The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes

(2016) Sam Tsz Wai Cheng et al.   PLoS One

Pancreatic β-Cell Adaptive Plasticity in Obesity Increases Insulin Production but Adversely Affects Secretory Function

(2015) Cristina Alarcon et al.   DIABETES

Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function

(2015) Aurora Merovci et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Oxidative and endoplasmic reticulum stress in β-cell dysfunction in diabetes

(2015) Sumaira Z Hasnain et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db/db mice

(2015) Yan-ju Wu et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The balance between adaptive and apoptotic unfolded protein responses regulates β-cell death under ER stress conditions through XBP1, CHOP and JNK

(2015) Jeng Yie Chan et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Proinsulin misfolding and endoplasmic reticulum stress during the development and progression of diabetes☆

(2015) Jinhong Sun et al.   MOLECULAR ASPECTS OF MEDICINE

Pancreatic β Cell Dedifferentiation in Diabetes and Redifferentiation following Insulin Therapy

(2014) Zhiyu Wang et al.   Cell Metabolism

Reversible changes in pancreatic islet structure and function produced by elevated blood glucose

(2014) Melissa F. Brereton et al.   Nature Communications

Glucotoxic conditions induce endoplasmic reticulum stress to cause caspase 3 mediated lamin B degradation in pancreatic β-cells: Protection by nifedipine

(2013) Khadija Syeda et al.   BIOCHEMICAL PHARMACOLOGY

Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin

(2013) Sunder Mudaliar et al.   Diabetes Technology & Therapeutics

Influence of chronic hyperglycemia on the loss of the unfolded protein response in transplanted islets

(2013) Stacey N Walters et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Defects in beta cell Ca2+ signalling, glucose metabolism and insulin secretion in a murine model of KATP channel-induced neonatal diabetes mellitus

(2011) R. K. P. Benninger et al.   DIABETOLOGIA

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

(2010) L. Zhang et al.   DIABETES OBESITY & METABOLISM

Secondary Consequences of β Cell Inexcitability: Identification and Prevention in a Murine Model of KATP-Induced Neonatal Diabetes Mellitus

(2009) Maria Sara Remedi et al.   Cell Metabolism

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Pancreatic β-cell mass in European subjects with type 2 diabetes

(2008) J. Rahier et al.   DIABETES OBESITY & METABOLISM

Glucolipotoxicity: Fuel Excess and β-Cell Dysfunction

(2008) Vincent Poitout et al.   ENDOCRINE REVIEWS